Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fluorodeoxyglucose F18 | 13 | 2024 | 149 | 2.150 |
Why?
|
| Positron-Emission Tomography | 14 | 2024 | 349 | 1.530 |
Why?
|
| Lung Neoplasms | 8 | 2024 | 2365 | 0.740 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2024 | 1133 | 0.700 |
Why?
|
| Radiopharmaceuticals | 6 | 2020 | 203 | 0.660 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 291 | 0.420 |
Why?
|
| Cysts | 2 | 2010 | 99 | 0.360 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2010 | 139 | 0.360 |
Why?
|
| Amyloid Neuropathies, Familial | 2 | 2022 | 37 | 0.360 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2024 | 104 | 0.330 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2015 | 2585 | 0.320 |
Why?
|
| Duodenal Diseases | 1 | 2010 | 25 | 0.320 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2023 | 184 | 0.310 |
Why?
|
| Multimodal Imaging | 3 | 2015 | 109 | 0.290 |
Why?
|
| Whole Body Imaging | 4 | 2015 | 40 | 0.260 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2016 | 1261 | 0.250 |
Why?
|
| Technetium | 2 | 2022 | 22 | 0.250 |
Why?
|
| Tumor Burden | 6 | 2023 | 321 | 0.230 |
Why?
|
| Prognosis | 5 | 2024 | 3911 | 0.220 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 11 | 0.220 |
Why?
|
| Radionuclide Imaging | 4 | 2018 | 189 | 0.220 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 25 | 0.220 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 31 | 0.210 |
Why?
|
| Subtraction Technique | 3 | 2011 | 125 | 0.210 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 125 | 0.200 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 68 | 0.200 |
Why?
|
| Aged | 13 | 2024 | 20434 | 0.200 |
Why?
|
| Retrospective Studies | 9 | 2024 | 10164 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 7061 | 0.190 |
Why?
|
| Neuroendocrine Tumors | 1 | 2024 | 136 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2003 | 239 | 0.180 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.180 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 333 | 0.180 |
Why?
|
| Colitis, Ulcerative | 1 | 2009 | 800 | 0.180 |
Why?
|
| Middle Aged | 13 | 2024 | 27573 | 0.180 |
Why?
|
| Female | 19 | 2024 | 48702 | 0.170 |
Why?
|
| Stomach Neoplasms | 1 | 2024 | 308 | 0.170 |
Why?
|
| Male | 19 | 2024 | 44557 | 0.170 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 666 | 0.170 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2018 | 626 | 0.160 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 242 | 0.160 |
Why?
|
| Humans | 29 | 2024 | 93515 | 0.160 |
Why?
|
| Sarcoidosis | 1 | 2020 | 92 | 0.160 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2020 | 145 | 0.150 |
Why?
|
| Image Enhancement | 3 | 2014 | 505 | 0.150 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 172 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 715 | 0.140 |
Why?
|
| Bone and Bones | 3 | 2011 | 273 | 0.140 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2011 | 337 | 0.120 |
Why?
|
| Parkinsonian Disorders | 1 | 2016 | 22 | 0.120 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2016 | 37 | 0.120 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2011 | 461 | 0.120 |
Why?
|
| Mutation | 2 | 2024 | 4272 | 0.120 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2016 | 88 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2018 | 396 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1194 | 0.110 |
Why?
|
| Cystic Duct | 1 | 2014 | 5 | 0.110 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2014 | 9 | 0.110 |
Why?
|
| Gallbladder | 1 | 2014 | 32 | 0.110 |
Why?
|
| Cholecystitis, Acute | 1 | 2014 | 9 | 0.110 |
Why?
|
| Adult | 9 | 2024 | 27918 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1546 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 233 | 0.100 |
Why?
|
| Aspartic Acid | 1 | 2013 | 66 | 0.100 |
Why?
|
| Prealbumin | 2 | 2022 | 41 | 0.090 |
Why?
|
| Sirolimus | 1 | 2013 | 176 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 1713 | 0.090 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2013 | 155 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 59 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2011 | 391 | 0.080 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2023 | 277 | 0.080 |
Why?
|
| Pituitary Neoplasms | 1 | 2010 | 73 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 361 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2012 | 317 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2013 | 378 | 0.070 |
Why?
|
| Bone Neoplasms | 2 | 2010 | 313 | 0.070 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 546 | 0.070 |
Why?
|
| Echo-Planar Imaging | 1 | 2007 | 51 | 0.070 |
Why?
|
| Remission Induction | 1 | 2009 | 738 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2013 | 813 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2007 | 172 | 0.060 |
Why?
|
| Neoplasm Staging | 3 | 2018 | 2017 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 6930 | 0.060 |
Why?
|
| Pattern Recognition, Automated | 1 | 2007 | 217 | 0.060 |
Why?
|
| Octreotide | 1 | 2024 | 29 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 1660 | 0.050 |
Why?
|
| Foreign-Body Migration | 1 | 2024 | 32 | 0.050 |
Why?
|
| Neoplasm Metastasis | 3 | 2013 | 1061 | 0.050 |
Why?
|
| Fibrin | 1 | 2024 | 86 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2024 | 101 | 0.050 |
Why?
|
| Vascular Calcification | 1 | 2024 | 46 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 2715 | 0.050 |
Why?
|
| Digestive System | 1 | 2003 | 40 | 0.050 |
Why?
|
| Inflammation | 1 | 2009 | 1050 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 8 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 15 | 0.050 |
Why?
|
| Device Removal | 1 | 2024 | 168 | 0.050 |
Why?
|
| Angiography | 1 | 2003 | 192 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 2303 | 0.050 |
Why?
|
| Biomarkers | 2 | 2022 | 1910 | 0.040 |
Why?
|
| Adolescent | 2 | 2018 | 9606 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2024 | 226 | 0.040 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.040 |
Why?
|
| Prevalence | 2 | 2020 | 1321 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 59 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 78 | 0.040 |
Why?
|
| Survival Rate | 2 | 2015 | 1948 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2024 | 9099 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2014 | 4560 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2441 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 474 | 0.040 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2018 | 20 | 0.040 |
Why?
|
| Reference Standards | 1 | 2018 | 146 | 0.030 |
Why?
|
| Observer Variation | 2 | 2010 | 570 | 0.030 |
Why?
|
| Neoplasms | 1 | 2012 | 3169 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1448 | 0.030 |
Why?
|
| Trinucleotide Repeats | 1 | 2016 | 30 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2016 | 83 | 0.030 |
Why?
|
| Calcium Channels | 1 | 2016 | 180 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1275 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 775 | 0.030 |
Why?
|
| Everolimus | 1 | 2013 | 34 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 876 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 295 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1931 | 0.020 |
Why?
|
| Infant | 1 | 2018 | 3220 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2018 | 3829 | 0.020 |
Why?
|
| Algorithms | 2 | 2011 | 1953 | 0.020 |
Why?
|
| Biological Transport | 1 | 2011 | 404 | 0.020 |
Why?
|
| Contrast Media | 1 | 2014 | 988 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 116 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 3054 | 0.020 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2011 | 292 | 0.020 |
Why?
|
| Pineal Gland | 1 | 2007 | 15 | 0.020 |
Why?
|
| Texas | 1 | 2007 | 131 | 0.020 |
Why?
|
| Bone Diseases | 1 | 2007 | 52 | 0.020 |
Why?
|
| Child | 1 | 2018 | 7355 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 608 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2006 | 212 | 0.010 |
Why?
|
| Automation | 1 | 2006 | 105 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 3830 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 5410 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 1922 | 0.010 |
Why?
|
| Software | 1 | 2006 | 670 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3476 | 0.010 |
Why?
|
| Lung | 1 | 2006 | 1366 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 2391 | 0.010 |
Why?
|
| Risk Factors | 1 | 2007 | 5899 | 0.010 |
Why?
|